Health economic evaluation of an integrated, cross-sectorial psycho-oncology - WP "Health economic evaluation" for the study "Integrated, cross-sectorial psycho-oncology (isPO)"

Health economic evaluation of an integrated, cross-sectorial psycho-oncology - WP "Health economic evaluation" for the study "Integrated, cross-sectorial psycho-oncology (isPO)" - isPO

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022396

Enrollment

300

Registered

2020-09-08

Start date

2019-01-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C00-C97

Interventions

Group 1: Intervention Group (IG): patients with an initial diagnosis cancer participating in the new form of care isPO Group 2: Control Group (CG): patients with an initial diagnosis cancer in standa

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: IG: • patients with an initial diagnosis cancer participating in the new form of care isPO • insured with the participating data-providing statutory health insurance companies BARMER, TK, AOK Rheinland/Hamburg or DAK Gesundheit • included isPO patients in the study until 30.09.2019. The sample group is a subgroup of the IG of the isPO research project. The procedure is justified by the time delay and availability of SHI claims data. Only completely provided data sets of isPO participants within the project duration can be considered for evaluation. CG: • insured persons with an initial diagnosis cancer who do not participate in isPO care and are treated in standard care • insured with the participating data-providing statutory health insurance companies BARMER, TK, AOK Rheinland/Hamburg or DAK Gesundheit Observation-/ Evaluation period: • from the defined index date (IG: enrolled date in isPO, KG: date of coded assured initial diagnosis of cancer based on routine SHI database), costs and consequences are descriptively evaluated over a period of 12 months using SHI claims data.

Exclusion criteria

Exclusion criteria: • no age of majority at baseline (age =01.10.2019) • CG: Non-fulfilment of the selection criteria of the comparison group from standard care (observation period, cancer diagnosis, gender, age, region) and other covariates for the application of a propensity score matching

Design outcomes

Primary

Measure	Time frame
Quantification of the costs and consequences of the intervention of patients in the isPO programme compared to patients in standard care from the SHI perspective. Evaluation based on SHI claims data: costs, for example inpatient cost, outpatient cost consequences, for example number of hospitalisation, physicians' contacts Evaluation period: 12 months from the defined baseline date (IG: enrolement date in the isPO care program, CG: date of assured initial diagnosis of cancer [diagnostic coding])	—

Measure

Time frame

Quantification of the costs and consequences of the intervention of patients in the isPO programme compared to patients in standard care from the SHI perspective. Evaluation based on SHI claims data: costs, for example inpatient cost, outpatient cost consequences, for example number of hospitalisation, physicians' contacts Evaluation period: 12 months from the defined baseline date (IG: enrolement date in the isPO care program, CG: date of assured initial diagnosis of cancer [diagnostic coding])

—

Countries

Germany

Contacts

Public ContactMichael Kusch

Universitätsklinikum Köln, Klinik I für Innere Medizin, Klinische Psychoonkologie, Versorgungsforschung

michael.kusch@uk-koeln.de+49(0)221 478-87410

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026